Switch theme
Sign up to access all valuation multiples
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
2013
49
LTM Revenue n/a
LTM EBITDA n/a
$25.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Relief Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Relief Therapeutics achieved revenue of $6.8M and an EBITDA of -$122M.
Relief Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Relief Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $6.9M | $6.8M | XXX | XXX | XXX |
| Gross Profit | -$18.6M | -$8.6M | XXX | XXX | XXX |
| Gross Margin | -271% | -125% | XXX | XXX | XXX |
| EBITDA | -$55.4M | -$122M | XXX | XXX | XXX |
| EBITDA Margin | -806% | -1791% | XXX | XXX | XXX |
| Net Profit | -$39.2M | -$57.4M | XXX | XXX | XXX |
| Net Margin | -571% | -842% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Relief Therapeutics's stock price is CHF 2 (or $3).
Relief Therapeutics has current market cap of CHF 30.6M (or $34.6M), and EV of CHF 22.3M (or $25.2M).
See Relief Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $25.2M | $34.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Relief Therapeutics has market cap of $34.6M and EV of $25.2M.
Relief Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Relief Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Relief Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $25.2M | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | XXX | XXX |
| EV/EBITDA | -0.2x | XXX | XXX | XXX |
| P/E | -0.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRelief Therapeutics's NTM/LTM revenue growth is n/a
Relief Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Relief Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Relief Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Relief Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1791% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 120% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 36% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 286% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 22% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 399% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Relief Therapeutics acquired XXX companies to date.
Last acquisition by Relief Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Relief Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Relief Therapeutics founded? | Relief Therapeutics was founded in 2013. |
| Where is Relief Therapeutics headquartered? | Relief Therapeutics is headquartered in Switzerland. |
| How many employees does Relief Therapeutics have? | As of today, Relief Therapeutics has 49 employees. |
| Is Relief Therapeutics publicy listed? | Yes, Relief Therapeutics is a public company listed on SWX. |
| What is the stock symbol of Relief Therapeutics? | Relief Therapeutics trades under RLF ticker. |
| When did Relief Therapeutics go public? | Relief Therapeutics went public in 2013. |
| Who are competitors of Relief Therapeutics? | Similar companies to Relief Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Relief Therapeutics? | Relief Therapeutics's current market cap is $34.6M |
| What is the current revenue growth of Relief Therapeutics? | Relief Therapeutics revenue growth between 2023 and 2024 was -1%. |
| Is Relief Therapeutics profitable? | Yes, Relief Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
